Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology

Neurology

Volumn 86, Issue 20, 2016, Pages 1887-1896

  Insel, Philip S ^a,b,c   Mattsson, Niklas ^c,d   Mackin, R Scott ^a,b   Schöll, Michael ^e,h   Nosheny, Rachel L ^a   Tosun, Duygu ^a,b   Donohue, Michael C ^f   Aisen, Paul S ^f   Jagust, William J ^g,h   Weiner, Michael W ^a,b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LUND UNIVERSITY   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANILINE DERIVATIVE; BIOLOGICAL MARKER; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; PEPTIDE FRAGMENT; RADIOPHARMACEUTICAL AGENT;

AGED; ANGULAR GYRUS; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; CINGULATE GYRUS; COGNITION ASSESSMENT; COHORT ANALYSIS; DISEASE MARKER; FEMALE; FRONTAL LOBE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NERVE CELL LESION; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TEMPORAL GYRUS; TEMPORAL LOBE; ATROPHY; BRAIN; CEREBROSPINAL FLUID; COGNITION; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; DISEASE COURSE; LONGITUDINAL STUDY; MENTAL HEALTH; METABOLISM; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; REGRESSION ANALYSIS;

AGED; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; ATROPHY; BIOMARKERS; BRAIN; COGNITION; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; ETHYLENE GLYCOLS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS SCHEDULE; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REGRESSION ANALYSIS;

EID: 84969242548     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002683     Document Type: Article

References (38)

1. Donohue MC, Jacqmin-Gadda H, Le Goff M, et al. Estimating long-Term multivariate progression from shortterm data. Alzheimers Dement 2014; 10: S400-S410.
2. Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer s pathological cascade. Lancet Neurol 2010; 9: 119-128.
3. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer s disease. N Engl J Med 2012; 367: 795-804.
4. Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207-216.
5. Hyman BT. Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 2011; 68: 1062-1064.
6. Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-To-moderate Alzheimer s disease. N Engl J Med 2014; 370: 311-321.
7. Sperling RA, Jack CR, Aisen PS. Testing the right target and right drug at the right stage. Sci Translational Med 2011; 3: 111cm33.
8. Karran E, Hardy J. Antiamyloid therapy for Alzheimer s disease: are we on the right road?. N Engl J Med 2014; 370: 377-378.
9. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin?. Sci Transl Med 2014; 6: 228fs13.
10. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer s disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-413.
11. Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012; 72: 578-586.
12. Jack CR, Vemuri P, Wiste HJ, et al. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 2011; 68: 1526-1535.
13. Villenueve S, Rabinovici GD, Cohn-Sheehy BI, et al. Existing Pittsburgh compound B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain 2015; 138: 2020-2033.
14. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer s disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012; 11: 1048-1056.
15. Filippini N, MacIntosh BJ, Hough MG, et al. Distinct patterns of brain activity in young carriers of the APOE-e4 allele. Proc Natl Acad Sci USA 2009; 106: 7209-7214.
16. Insel PS, Mattsson N, Donohue MC, et al. The transitional association between b-Amyloid pathology and regional brain atrophy. Alzheimers Dement 2015; 11: 1171-1179.
17. Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of beta-Amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005; 51: 336-345.
18. Jack CR, Bernstein MA, Fox NC, et al. The Alzheimer s Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008; 27: 685-691.
19. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002; 33: 341-355.
20. Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA. The Alzheimer s Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010; 6: 221-229.
21. Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011; 32: 1207-1218.
22. Reitan R. Validity of the Trail-Making test as an indication of organic brain damage. Percept Mot Skills 1958; 8: 271-276.
23. Wechsler DA. Wechsler Adult Intelligence Scale-Revised. New York: Psychological Corporation; 1987.
24. Kaplan EF, Goodglass H, Weintraub S. The Boston Naming Test, 2nd ed. Philadelphia: Lea & Febiger; 1982.
25. Rey A. l Examen Clinique En Psychologie. Paris: Presses Universitaires de France; 1964.
26. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer s disease. Am J Psychiatry 1984; 141: 1356-1364.
27. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities of older adults in the community. J Gerontol 1982; 37: 323-329.
28. Morris JC. Clinical dementia rating. Neurology 1993; 43: 2412-2414.
29. Insel PS, Mattsson N, Mackin RS, et al. Biomarkers and cognitive endpoints to optimize trials in Alzheimer s disease. Ann Clin Transl Neurol 2015; 2: 534-547.
30. Wood SN. Generalized Additive Models: An Introduction with R. Boca Raton, FL: Chapman and Hall/CRC Press; 2006.
31. Wood SN. Monotonic smoothing splines fitted by cross validation. SIAM J Sci Comput 1994; 15: 1126-1133.
32. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995; 57: 289-300.
33. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer s disease: recommendations from the National Institute on Aging-Alzheimer s Association workgroups on diagnostic guidelines for Alzheimer s disease. Alzheimers Dement 2011; 7: 280-292.
34. Mattsson N, Insel PS, Donohue M, et al. Predicting reduction of cerebrospinal fluid b-Amyloid 42 in cognitively healthy controls. JAMA Neurol 2015; 72: 554-560.
35. Mattsson N, Insel PS, Donohue M, et al. Independent information from cerebrospinal fluid amyloid-b and florbetapir imaging in Alzheimer s disease. Brain 2015; 138: 772-783.
36. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E e4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer s disease. Proc Natl Acad Sci 2001; 98: 3334-3339.
37. Mackin RS, Insel P, Zhang J, et al. Cerebrospinal fluid a-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer s disease. J Alzheimers Dis 2015; 43: 1007-1016.
38. Keage HA, Hunter S, Matthews FE, et al. TDP-43 pathology in the population: prevalence and associations with Dementia and age. J Alzheimers Dis 2014; 42: 641-650.